Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country

Hikmat Abdel-Razeq,1,2 Baha Sharaf,1 Suhaib Khater,1 Huda Jafar Baidoun,2 Hira Bani Hani,1 Ayat Taqash,3 Osama El Khatib,1 Sarah Edaily,1 Mahmoud Abunasser,1 Faris Tamimi,1 Yosra Nabeel Al-Masri,1 Tamer Moh’d Waleed Al-Batsh,1 Anas Zayed,1 Tala Ghatasheh,1 Tala Radaideh1 1Department of Internal Medi...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Dove Medical Press 2024-09-01
סדרה:	ImmunoTargets and Therapy
נושאים:	metastatic breast cancer mbc cdk4/6 inhibitors ribociclib aromatase inhibitors fulvestrant
גישה מקוונת:	https://www.dovepress.com/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-peer-reviewed-fulltext-article-ITT
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!